ENTERA BIO LTD. 2018 EQUITY INCENTIVE PLAN STOCK OPTION AWARD AGREEMENT - ISRAELI EMPLOYEES – TRUSTEE CAPITAL GAIN ROUTEAward Agreement • March 28th, 2019 • Entera Bio Ltd. • Biological products, (no disgnostic substances)
Subject to the terms and conditions set forth in this grant letter (the “Grant Letter”) and the award agreement set forth in Exhibit A (the Grant Letter and Exhibit A, collectively this “Agreement”), Entera Bio Ltd., a company organized under the laws of the State of Israel (the “Company”), has granted you as of the Grant Date set forth below an option to purchase Shares (the “Award”). The Award is granted under and is subject to the Entera Bio Ltd. 2018 Equity Incentive Plan (together with the Israeli Sub Plan, the “Plan”). Unless defined in this Agreement, capitalized terms shall have the meanings assigned to them in the Plan. The provisions of the Plan shall control in the event of a conflict among the provisions of the Plan, this Agreement and any descriptive materials provided to you.
RESEARCH COLLABORATION AND LICENSE AGREEMENT by and betweenResearch Collaboration and License Agreement • March 28th, 2019 • Entera Bio Ltd. • Biological products, (no disgnostic substances) • New York
This Research Collaboration and License Agreement (“Agreement”) is entered into as of December 10, 2018 (the “Effective Date”) by and between Amgen Inc., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320, USA (“Amgen”) and EnteraBio Ltd., an Israeli company having an address at Minrav Building, 5th Floor, PO Box 12117, Jerusalem 91220, Israel (“EnteraBio”). Amgen and EnteraBio are each hereafter referred to individually as a “Party” and together as the “Parties”.
